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Abstract 26 
Background Enteroviruses (EVs) have been linked to the pathogenesis of several diseases and 27 
there is a collective need to develop improved methods for the detection of these viruses in tissue 28 
samples.  29 
Objectives This study evaluates the relative sensitivity of immunohistochemistry (IHC), 30 
proteomics, in situ hybridization (ISH) and RT-PCR to detect one common EV, Coxsackievirus B1 31 
(CVB1), in acutely infected human A549 cells in vitro. 32 
Study design A549 cells were infected with CVB1 and diluted with uninfected A549 cells to 33 
produce a limited dilution series in which the proportion of infected cells ranged from 10-1 to 10-8.  34 
Analyses were carried out by several laboratories using IHC with different anti-EV antibodies, ISH 35 
with both ViewRNA and RNAScope systems, Liquid Chromatography Multiple Reaction 36 
Monitoring Mass Spectrometry (LC/MRM/MS/MS), and two modifications of RT-PCR.   37 
Results RT-PCR was  the  most  sensitive  method for  EV detection  yielding  positive  signals  in  the  38 
most diluted sample (10-8). LC/MRM/MS/MS detected viral peptides at dilutions as high as 10-7. 39 
The sensitivity of IHC depended on the antibody used, and the most sensitive antibody (Dako clone 40 
5D8/1) detected virus proteins at a dilution of 10-6, while ISH detected the virus at dilutions of 10-4.  41 
Conclusions All methods were able to detect CVB1 in infected A549 cells. RT-PCR was most 42 
sensitive followed by LC/MRM/MS/MS and then IHC. The results from this in vitro survey suggest 43 
that all methods are suitable tools for EV detection but that their differential sensitivities need to be 44 
considered when interpreting the results from such studies.  45 
46 
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Background 50 
Enterovirus1 (EV) infections are common in all age groups. They are usually asymptomatic or cause 51 
only mild respiratory symptoms, but can also lead to more severe illness including hand, foot and 52 
mouth disease, myocarditis, meningitis, encephalitis, pancreatitis, systemic infection in newborns 53 
and paralysis. EV infections may also play a role in the pathogenesis of chronic diseases such as 54 
dilated cardiomyopathy (1), chronic fatigue syndrome (2) and type 1 diabetes2 (T1D) (3-5).   55 
Laboratory diagnosis of EV infection is based on virus detection in stools, nasal/throat swabs or 56 
cerebrospinal fluid, as well as on EV-specific antibody responses in serum. However, studies 57 
evaluating the pathogenesis of EV infections and their possible role in chronic diseases (where 58 
levels of viral infection may be low but persistent) require additional technologies and there is an 59 
increasing need for direct virus detection in tissue samples. Traditionally, EVs are detected in tissue 60 
samples either by RT-PCR or immunohistochemistry3 (IHC). In addition to these, the new single 61 
molecule hybridization (6,7) as well as mass spectrometry/proteomics technologies offer new 62 
opportunities for viral detection. However, there are no previous reports in which the performance 63 
of these various technologies has been evaluated in relation to one another.  64 
Objectives 65 
The aim of the study was to evaluate the relative sensitivities of proteomics, ISH, IHC and RT-PCR 66 
methods to detect one common EV, Coxsackievirus B14 (CVB1), using human A549 cells diluted 67 
to contain differing ratios of uninfected to in vitro EV-infected cells.  68 
 69 
                                                             
1 EV, enterovirus 
2 T1D, type 1 diabetes 
3 IHC, immunohistochemistry 
4 CVB, Coxsackievirus B 
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Study design 70 
Preparation of EV-infected cell arrays 71 
Human A549 alveolar basal epithelial cells were grown in monolayers in Nutrient Mixture F-12 72 
Ham, N 6658 (Sigma-Aldrich®) medium in T175 bottles and infected with CVB1, ATCC strain 73 
(10-15 MOI). The infection was stopped at four different time points (1 h, 2 h, 4 h, and 6 h post 74 
infection) to obtain a series of infected cells representing different stages of viral replication cycle. 75 
The cells from different time points were mechanically detached, pooled and washed with the 76 
growth medium. The cells were then immediately diluted with uninfected A549 cells to produce a 77 
dilution series ranging from 10-1 to  10-8,  as  well  as  an  undiluted  sample  (positive  control)  and  a  78 
sample of uninfected A549 cells (negative control). Each dilution aliquot was further divided into 79 
ten sub-aliquots, each containing about 1 million cells. These sub-aliquots were fixed or stored in an 80 
optimal way for each of the different methodologies employed. Some of the aliquots were fixed in 81 
10 % neutral-buffered formalin for 24 h and paraffin-embedded using standard procedures for IHC 82 
and ISH analyses. The rest were quickly frozen in liquid nitrogen and stored at -70°C for RT-PCR 83 
and proteomics analyses. From the individual formalin-fixed paraffin-embedded5 (FFPE) samples, a 84 
cell microarray was created using TMA Master (3D Histech Kft, Hungary) and 5 µm-thick sections 85 
were cut for histological stainings. 86 
RT-PCR 87 
RT-PCR was performed in two different laboratories (Tampere and Uppsala), each analyzing 88 
similar  aliquots  of  the  dilution  series.  In  Tampere,  RNA  was  extracted  from  140  µl  cell  sample  89 
using  the  Viral  RNA  Kit  (Qiagen,  Hilden,  Germany),  and  real-time  RT-PCR  was  performed  as  90 
previously described (8). In Uppsala, viral RNA was extracted from 100 µl using RNeasy Mini kit 91 
                                                             
5 FFPE, formalin-fixed paraffin-embedded 
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(Qiagen). 50 ng total RNA/sample were primed with virus specific primers and reverse transcribed 92 
to cDNA with SuperScriptIITM RT (Invitrogen) according to the manufacturer’s instructions. A 93 
semi-nested EV PCR was performed as described previously (3). 94 
Proteomics 95 
The dilution series samples were solubilized using 50% Trifluoroethanol in 50 mM ammonium 96 
bicarbonate as previously described (9). Protein concentration was determined by bicinchoninic 97 
acid6 (BCA) assay (Pierce, Rockford, Ill.). Concentration normalized samples from each of the 98 
dilution steps were reduced and alkylated as previously described (10). Proteins were digested with 99 
trypsin at a ratio of 1:50 at 37oC for 18 h to generate peptides. The peptides were purified using C18 100 
columns, eluted using 80% acetonitrile in 0.1% formic acid and dried in a SpeedVac. Peptides were 101 
reconstituted in 0.1% formic acid prior to Liquid chromatography multiple reaction monitoring 102 
mass spectrometry7 (LC/MRM/MS/MS). LC/MRM/MS/MS on a triple quadrupole (QqQ) mass 103 
spectrometer8 provides superior rapid, sensitive, and specific identification and quantitation of 104 
targeted compounds in highly complex samples (11,12).   105 
LC/MRM/MS  analysis  of  the  tryptic  peptides  from  the  10  A549  dilution  series  cell  samples  was  106 
performed on a 4000 QTRAP® mass spectrometer coupled to a Tempo NanoLC system  (ABSciex, 107 
Foster City, CA)  (10). Skyline was used to generate and optimize tryptic peptides and tandem 108 
MS/MS fragmentation data for developing MRM transitions pairs for CVB1 peptides (13). A CVB1 109 
2C protein peptide SVATNLIGR was selected for subsequent analysis and quantitation based on its 110 
abundance and high signal intensities for both the precursor ion (Q1 m/z) and fragment ions (Q3 111 
m/z) and absence of signals in non-infected A549 cells. MRM Pilot  TM software (ABSciex) was 112 
                                                             
6 BCA, bicinchoninic acid 
7 LC/MRM/MS/MS, liquid chromatography multiple reaction monitoring mass spectrometry 
8 QqQ, triple quadrupole mass spectrometer 
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used to optimize the assay conditions for the SVATNLIGR peptide with the following transition 113 
pairs of 465.7720/572.3515 and 465.7720/744.4363. The Q1 m/z (465.7720) for the MH2+ peptide 114 
parent mass and the Q3 m/zs correspond to y5 (572.3515) and y7 (744.4363) fragment ions. The 115 
final MRM assay conditions are detailed in Supplementary data. 116 
The tryptic peptides corresponding to 1.6 ȝg of sample were injected and analyzed  for each sample. 117 
The samples were sequentially analyzed starting with the non-infected samples and the low 118 
dilutions, to the non-diluted samples with multiple washing steps using blanks (buffer A) between 119 
each sample to avoid carry-over. Each sample was analyzed in duplicate experiments. Relative 120 
quantitation was achieved by comparing the area under the curve for the peptide transition pairs in 121 
the extracted ion chromatograms9 (XIC) for each dilution step. The acquired data were processed 122 
and analyzed using Analyst 1.2 (ABSciex). 123 
Immunohistochemistry 124 
IHC was performed in three laboratories (Tampere, Exeter and Uppsala). Primary analyses were 125 
done  using  a  commercially  available  antibody  raised  against  EV  VP110 protein (clone 5D8/1; 126 
DAKO, Glostrup, Denmark). In Tampere and Exeter, IHC was performed as previously described 127 
(5,14,15). In Uppsala, the sections were counterstained with haematoxylin (DAKO) before addition 128 
of the primary antibody (diluted 1:2000) in autostainer Link 48 DAKO. Visualization was achieved 129 
with the DAKO Envision K8000. In addition, polyclonal antibodies produced in rabbits (see 130 
Supplementary) against each of the viral capsid proteins VP1, VP2, VP3 and VP4 of CVB4 131 
Tuscany strain, were analyzed in the Tampere and Exeter laboratories. Antibodies from the first 132 
bleed (VP1A and VP3A) and from the last  bleed (VP1B, VP2B, VP3B and VP4B) were used. In 133 
Tampere, staining was performed using the automated system and similar conditions to those for 134 
                                                             
9 XIC, extracted ion chromatogram 
10 VP, viral protein 
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clone 5D8/1. In Exeter, following heat-induced epitope retrieval in 10mM citrate, pH6.0, the VP1-135 
VP4 antibodies were incubated for 1h at room temperature. The DAKO Envision Detection System 136 
was used for antigen detection as per the manufacturer’s instructions and sections were 137 
counterstained with haematoxylin. The concentrations of CVB4 VP1-VP4 antibodies used in both 138 
laboratories are detailed in Supplementary Table 1. 139 
In situ hybridization 140 
ISH  assays  were  performed  in  two  laboratories  (Tampere  and  Gainesville).  In  Tampere,  the  141 
QuantiGene® ViewRNA (Affymetrix, Santa Clara, California, USA) was used with two different 142 
EV-specific  probe  sets  (EV  AB  and  CVB1),  according  to  the  manufacturer’s  instructions  and  as  143 
previously described (6). In Gainesville, ISH was performed using the RNAscope 2.0 High 144 
Definition Assay (Advanced Cell Diagnostics, Hayward, California, USA) according to the 145 
manufacturer’s instructions. Two EV-specific probes were tested to detect serotypes CVB1-6 and 146 
CVB3. Deparaffinized sections were hybridized to probes followed by amplification by serial 147 
application of amplifiers followed by peroxidase labels and detection with DAB.   148 
 149 
Results 150 
RT-PCR 151 
Viral  RNA  was  detected  by  RT-PCR  in  all  samples  although  the  semi-nested  method  was  most  152 
sensitive.  This yielded a positive signal from even the most dilute sample (10-8) whereas the real-153 
time RT-PCR method gave a positive signal in the second most dilute sample (10-7). Ct values from 154 
real-time  RT-PCR  experiments  with  different  dilutions  of  infected  cells  are  shown  in  155 
Supplementary Table 2.  156 
Proteomics 157 
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MS-based targeted LC/MRM/MS/MS assay focused on the CVB1 2C protein peptide SVATNLIGR 158 
and the peptide signal was detectable at cell dilutions as high as 10-7. Figure  1  shows  the  159 
LC/MRM/MS/MS results for the relative abundance of the 2C protein peptide in undiluted, virus-160 
infected  cells.  It  also  shows  the  detection  of  the  MRM  transition  pairs  signals,  and  the  enhanced  161 
product ion scan11 (EPI) showing the MS/MS fragmentation spectrum for the peptide.  162 
 163 
Figure 1. Multiple reaction monitoring assay for CVB1 virus peptides. The total ion chromatogram and 164 
MRM peaks are shown in panels A and B. The extracted ion chromatogram (XIC) for the Protein 2C peptide 165 
is shown in panel C and the enhanced product ion scan (EPI) spectrum with the Q3 y5 and y7 fragment ions 166 
are shown in panel D. These two ions are the most intense in the tandem mass spectrum and their primary 167 
sequences correspond to the following c-terminus fragments of the peptide. y5 NLIGR (m/z = 572.3515) and  168 
y7 ATNLIGR (m/z = 744.4363). 169 
                                                             
11 EPI, enhanced product ion scan 
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 170 
Figure 2 shows extracted ion chromatograms of the two transition pairs 465.7720/572.3515 (red) 171 
and 465.7720/744.4363 (blue) for the non-diluted, infected A549 cells (Panel A), the dilution series 172 
of the infected cells (Panels B - J) and the non-infected A549 cells (Panel  K). The relative intensity 173 
and the accompanying signal for the MRM assay decreases from that of the peptide. 174 
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Figure 2. MRM Detection of CVB1 peptide in A549 cells LC/MRM/MS. Extracted ion chromatograms of 176 
the two transition pairs 465.7720/572.3515 (red) and 465.7720/744.4363 (purple) for the non-diluted CVB1 177 
infected A549 cells panel (A), the dilution series of the infected cells (Panels B - I) and the non-infected 178 
A549  cells  (Panel   J).  The  MRM peaks  in  the  samples  are  marked  with  a  red  arrow.  Note  the  absence  of  179 
signal (?) in Panel J. In panel A, the Zoom shows an expansion of the baseline to show the well resolved 180 
peaks of the extracted ion chromatograms of the two MRM transition pairs. 181 
Immunohistochemistry 182 
IHC also proved to be a sensitive method for detection of viral protein but was less sensitive than 183 
semi-nested RT-PCR, real-time RT-PCR and LC/MRM/MS/MS. IHC detected viral protein in 184 
virtually every cell in the undiluted sample, but the proportion of virus-positive cells decreased 185 
linearly as the dilution increased. Clone 5D8/1 was the most sensitive antibody tested detecting 186 
virus-positive cells at dilutions equal to or lower than 10-4 in Uppsala, 10-5 in Tampere and 10-6 in 187 
Exeter. At dilutions from 10-3 and beyond, the number of virus-positive cells was scarce, with only 188 
occasional cells stained positively (Fig. 3). In Tampere and Exeter, antibodies raised against CVB4 189 
viral capsid proteins, stained efficiently the infected cells diluted over the range 10-2 to  10-4. The 190 
intensity of the staining with these antibodies varied to some extent, with the VP1 (10 -3) and VP3 191 
(10-4) antibodies giving the highest sensitivities which were comparable in both Tampere and 192 
Exeter laboratories. 193 
In situ hybridization 194 
Both ISH methods (ViewRNA and RNAscope) demonstrated equal sensitivity, regardless of the 195 
probe used, detecting the virus at dilutions of 10-4 (Fig. 4). In the undiluted sample, almost all cells 196 
were EV-positive, and the number of positive cells decreased linearly as the ratio of CVB1-infected 197 
cells to uninfected cells was reduced.  198 
Comparison of the sensitivity results between the methodologies is summarized in Table 1. 199 
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Figure 3. Detection of CVB1 in infected A549 and uninfected A549 cells (FFPE) with different antibodies; 222 
commercial DAKO clone 5D8/1 and in-house anti-CVB4 antibodies VP1A, VP1B, VP2B, VP3A, VP3B and 223 
VP4B. Example micrographs of uninfected control, CVB1 infected undiluted sample and CVB1 infected 224 
dilution 10-1 are shown. 40X magnification. Scale bar = 50µm. 225 
 226 
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 228 
 229 
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 232 
 233 
 234 
 235 
 236 
Figure 4. Detection of CVB1 in infected A549 and in uninfected A549 cells (FFPE) using two different 237 
commercially available ISH (ViewRNA and RNAscope) methods. Example micrographs of uninfected 238 
control, CVB1 infected undiluted sample and CVB1 infected dilution 10-1 are shown. 40X magnification. 239 
Scale bar = 50µm. 240 
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Table 1. Comparison of the sensitivity of different methodologies to detect CVB1 in A549 cells. 250 
Method Sensitivity 
(dilution) 
RT-PCR (frozen cells)  
          semi-nested (Uppsala) 10-8 
          real-time (Tampere) 10-7 
Proteomics (frozen cells)  
          LC/MRM/MS/MS 10-7 
          MRM 10-7 
IHC (FFPE cells)  
          anti-EV VP1: Clone 5D8/1 10-4 - 10-6 
          anti-CVB4 VP1, -VP2, -VP3, -VP4 10-2 – 10-4 
ISH (FFPE cells)  
          probes: EV AB1, CVB12 (Affymetrix) 10-4 
          probe: CVB1-6, CVB3 (RNAscope) 10-4 
1 targets members of EV species A and B; 2 serotype-targeted probe 251 
 252 
Discussion 253 
The present study provides important information to guide the selection of assays capable of 254 
optimally detect EVs in infected cells. Although the conditions prevailing in mammalian cells 255 
infected in vitro do not completely resemble those in clinical  tissue samples,  the results provide a 256 
firm indication of the sensitivity and specificity of each method. 257 
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All methods tested were able to detect CVB1 with good sensitivity. However, depending on the 258 
method used, the detection limit varied and RT-PCR was found to be the most sensitive one.  259 
The new LC/MRM/MS/MS technology demonstrated also high sensitivity, while its sensitivity 260 
might be still further improved by use of higher capacity columns that allow the loading of larger 261 
amounts of peptides. This technology has the particular advantage that identification and validation 262 
experiments are performed at the same time; the overlapping extracted ion chromatograms for the 263 
MRM transition pairs provide confirmation that the signals are derived from the same peptide and 264 
the MS/MS spectrum data can be used for protein identification in database searches. These data 265 
highlight the potential utility of using modern sensitive MS approaches to identify viral sequences 266 
with a relatively high sensitivity, suggesting that its applicability for virus detection in human 267 
samples should be evaluated in detail. The differences in sensitivities observed among the 268 
laboratories using IHC approaches with the same antibody, and also the laboratories employing 269 
ISH, could be explained by the low number of virus-positive cells present in the more diluted 270 
samples. Once these dilutions are reached, the actual number of virus-positive cells is very low (1-2 271 
cells per field); thus, positivity may vary from one section to another when cells are plated for 272 
analysis. Importantly, the different antisera tested exhibited broadly similar profiles among the 273 
different laboratories with the 5D8/1 clone consistently demonstrating the highest sensitivity. ISH 274 
sensitivity depends on a number of variables including the affinity with which the relevant probe 275 
sets bind to the CVB1 genome. Therefore, we cannot conclude that IHC and ISH data have yielded 276 
absolute sensitivities in each laboratory, but rather they provide an indication of the sensitivity 277 
range of each method.  278 
Each of the tested methods clearly has its own advantages. The proteomics-based 279 
LC/MRM/MS/MS provides important molecular information about the detected viruses based on 280 
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peptide sequences. We have also previously used mass spectrometry imaging12 (MSI) to identify 281 
insulin and other proteins in pancreas tissue since the technology is useful for the identification and 282 
determination  of  the  spatial  distribution  of  molecules  in  tissues  (16).   The  preservation  of  tissue  283 
morphology is a clear advantage of IHC and ISH, thereby making it possible to localize the virus in 284 
individual cells. ISH appeared to be less sensitive than IHC, but this varied according to the type of 285 
antibodies used in IHC. The main advantage of RT-PCR is its high sensitivity and the possibility to 286 
derive sequence information from the viral genome.  287 
This study also has certain limitations. Firstly, it was based on infected cells and not ex-vivo tissue 288 
samples, and therefore the relative sensitivity of each assay might be different when tissues are 289 
examined. Secondly, a single EV strain was used and, theoretically, the binding of antibodies, 290 
probes and primers to different EV strains may differ. However, the used antibodies bind to several 291 
different EV serotypes and strains, the used PCR primers amplify practically all EVs, the used ISH 292 
techniques allow specific probes to be designed, enabling the detection of the virus of interest (6), 293 
and proteomics analyses are not dependent on the EV type, suggesting that other EV strains should 294 
give comparable results. Third, it is difficult to exclude the possibility that in spite of the repeated 295 
washes of the infected cells during the preparation of infected cell arrays, remnants of extracellular 296 
viral peptides and RNA may have remained in the samples. This could have led to overestimation 297 
of the PCR and proteomics sensitivity, which can detect both intracellular and extracellular viruses 298 
compared to IHC and ISH, which mainly detect intracellular viruses. In addition, one needs to 299 
consider the fact that the sensitivity of RT-PCR and proteomics may depend on the sample volume, 300 
while ISH and IHC methods detect the virus on a thin (5 µm) tissue section. Thus, the results should 301 
be put into the context of these limitations and the use of more than one of these assays is 302 
recommended to reach optimal sensitivity and specificity.     303 
                                                             
12 MSI, mass spectrometry imaging 
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In conclusion, all methods proved suitable for the detection of EV in FFPE or frozen samples. The 304 
new proteomics technologies offer one of the most attractive alternatives for frozen tissues, being 305 
relatively sensitive and providing sequence information about the detected virus. On the other hand, 306 
the  new  non-radioactive  ISH  methods  work  well  in  FFPE  samples.  Even  if  IHC  and  proteomics  307 
were relatively sensitive, RT-PCR remains one of the most sensitive methods when frozen or fresh 308 
samples are available. Importantly, this effort was launched as part of the collaborative efforts of 309 
the  JDRF  nPOD  Working  Group,  and  these  results  are  guiding  virus  analyses  of  pancreas  310 
specimens collected from T1D patients.  311 
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